Literature DB >> 15373935

European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach.

R H Vander Stichele1, M M Elseviers, M Ferech, S Blot, H Goossens.   

Abstract

BACKGROUND: Europe is a continent with strong public healthcare systems, but diverging antibiotic policies and resistance patterns. AIMS: To describe the performance and methodological approach in a retrospective data collection effort (1997-2001), through an international network of surveillance systems, aiming to collect publicly available, comparable and reliable data on antibiotic use in Europe.
METHODS: A central multidisciplinary management team co-ordinated a network of national representatives, liasing with national data providers and bodies responsible for antibiotic policy. The data collected were screened for bias, using a checklist. We focused on detection bias in sample and census data; errors in assigning medicinal product packages to the Anatomical Therapeutic Chemical Classification (ATC); errors in calculations of defined daily doses (DDD) per package; bias by over-the-counter sales and parallel trade; and bias in ambulatory care (AC)/hospital care (HC) mix. Datasets were corrected after national feedback, and classified as valid; valid but with minor bias; not valid.
RESULTS: Of the 31 participating countries, 21 countries delivered AC data suitable for cross-national comparison (14 for all 5 years). Of these, 17 countries provided data on a quarterly basis for at least 1 year. For HC, 14 countries were able to deliver valid data (nine for all 5 years). A valid estimate of the total exposure of national populations to human antibiotic consumption could be made in 17 countries.
CONCLUSION: In cross-national comparisons of antibiotic consumption in Europe, methodological rigour in correcting for various sources of bias and checking the validity of ATC/DDD assignment is needed. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373935      PMCID: PMC1884596          DOI: 10.1111/j.1365-2125.2004.02164.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Different versions of the anatomical therapeutic chemical classification system and the defined daily dose--are drug utilisation data comparable?

Authors:  M Rønning; H S Blix; B T Harbø; H Strøm
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

Review 2.  Antibiotic use in long-term-care facilities: many unanswered questions.

Authors:  M Loeb
Journal:  Infect Control Hosp Epidemiol       Date:  2000-10       Impact factor: 3.254

3.  Variation in antibiotic use in the European Union.

Authors:  O Cars; S Mölstad; A Melander
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

Review 4.  Making sense of antimicrobial use and resistance surveillance data: application of ARIMA and transfer function models.

Authors:  D L Monnet; J M López-Lozano; P Campillos; A Burgos; A Yagüe; N Gonzalo
Journal:  Clin Microbiol Infect       Date:  2001       Impact factor: 8.067

5.  Antibiotic prescription rates vary markedly between 13 European countries.

Authors:  Sigvard Mölstad; Cecilia Stålsby Lundborg; Anna-Karin Karlsson; Otto Cars
Journal:  Scand J Infect Dis       Date:  2002

Review 6.  Community acquired infections and bacterial resistance.

Authors:  H Goossens; M J Sprenger
Journal:  BMJ       Date:  1998-09-05

7.  Antibiotic armageddon.

Authors:  C M Kunin
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

8.  Use of antimicrobial agents and drug resistance.

Authors:  M N Swartz
Journal:  N Engl J Med       Date:  1997-08-14       Impact factor: 91.245

9.  Cross-cultural differences in lay attitudes and utilisation of antibiotics in a Belgian and a Dutch city.

Authors:  Reginald Deschepper; Robert H Vander Stichele; Flora M Haaijer-Ruskamp
Journal:  Patient Educ Couns       Date:  2002 Oct -Nov

10.  [Infections and use of antibiotics in nursing homes].

Authors:  A Bucher; N Sorknes; K Lundqvist; K Rønning
Journal:  Tidsskr Nor Laegeforen       Date:  2001-03-10
View more
  32 in total

1.  [Defined daily doses: a high antibioptic prescription rate?].

Authors:  Juan Simó Miñana
Journal:  Aten Primaria       Date:  2011-10-19       Impact factor: 1.137

Review 2.  [Use of prescription drugs in Spain and Europe].

Authors:  Juan Simó Miñana
Journal:  Aten Primaria       Date:  2011-10-22       Impact factor: 1.137

3.  Assessing the impact of national antibiotic campaigns in Europe.

Authors:  M Filippini; L G González Ortiz; G Masiero
Journal:  Eur J Health Econ       Date:  2012-06-17

4.  Antimicrobial use and indication-based prescribing among general practitioners in Eastern Croatia: comparison with data from the European Surveillance of Antimicrobial Consumption project.

Authors:  Željko Vojvodić
Journal:  Croat Med J       Date:  2010-12       Impact factor: 1.351

5.  Indicators of prescribing quality in drug utilisation research: report of a European meeting (DURQUIM, 13-15 May 2004).

Authors:  J L Hoven; F M Haaijer-Ruskamp; R H Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2004-12-09       Impact factor: 2.953

6.  Hospital antibiotic management in Hungary--results of the ABS maturity survey of the ABS International group.

Authors:  Gabor Ternak; Istvan Almasi; Eva Rakoczi
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

7.  How can we fight against antimicrobial- resistant bacteria in the World Health Organization Western Pacific Region?

Authors:  Yoshiaki Gu; Mitsuo Kaku
Journal:  Western Pac Surveill Response J       Date:  2012-07-30

Review 8.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

9.  Variation in outpatient antibiotic prescribing in the United States.

Authors:  Michael A Steinman; Katherine Y Yang; Sepheen C Byron; Judith H Maselli; Ralph Gonzales
Journal:  Am J Manag Care       Date:  2009-12       Impact factor: 2.229

10.  Molecular epidemiology of macrolide-resistant Streptococcus pneumoniae isolates in Europe.

Authors:  Ralf René Reinert; Adrian Ringelstein; Mark van der Linden; Murat Yücel Cil; Adnan Al-Lahham; Franz-Josef Schmitz
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.